



350 - 4243 Glanford Ave. Victoria, BC Canada V8Z 4B9  
Tel: (250) 744-2811 Fax: (250) 744-2877 [www.stressgen.com](http://www.stressgen.com)

## STRESSGEN ADDED TO THE TSE 300 COMPOSITE INDEX

FOR IMMEDIATE RELEASE

OCTOBER 24<sup>th</sup>, 2000

**Victoria, British Columbia** - StressGen Biotechnologies Corp. (TSE: SSB) is pleased to announce that it has been selected to join the Toronto Stock Exchange 300 Composite Index (TSE 300) and has also been added to the Standard & Poor's/TSE SmallCap Index in the Health Care sector. This inclusion was effective as of the close of business on Monday, October 23rd, 2000.

"I believe this is a milestone for StressGen, and one that reflects both the Company's emergence as a leader within the biotech industry and also the growing importance of the life sciences sector to our economy," said Daniel Korpilinski, President and CEO of StressGen Biotechnologies. "We are all very proud that StressGen is now a member of this select group of Canadian public companies."

Comprised of 300 of Canada's larger public companies traded on the Toronto Stock Exchange, the TSE 300 was created in 1977 by the Toronto Stock Exchange and is maintained by S&P. This index is considered a benchmark used to measure the price performance of the broad Canadian equity market. Inclusion in the TSE 300 is made only after review by S&P and in accordance with certain criteria.

StressGen Biotechnologies Corporation is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of virally-induced infections and related cancers. StressGen's lead product HspE7 targets a variety of precancerous and cancerous conditions caused by Human Papillomavirus (HPV), a sexually transmitted disease. The Company has active Phase II HspE7 studies in women with high-grade cervical dysplasia and cervical cancer, as well as a Phase II study in anal dysplasia. In addition, StressGen plans to initiate a Phase II HspE7 study in genital warts and a Phase III HspE7 study in anal dysplasia before the end of the year. StressGen has also initiated research studies to evaluate the technology in the treatment of asthma and allergy as well as Hepatitis B. Through its Biochemical Division, StressGen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

-30-

Contact: Elisabeth Whiting, Director, Corporate Communications & Investor Relations  
StressGen Biotechnologies, 350-4243 Glanford Ave. Victoria, BC V8Z 4B9  
Tel: 250-744-2811 Fax: 250-744-3331 [ewhiting@stressgen.com](mailto:ewhiting@stressgen.com)

*This foregoing press release may contain statements that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "will", "intends", "plans", "expects" and words of similar import. Such statements may constitute "forward-looking" statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements implied by such statements. Such factors include, but are not limited to, those with respect to the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), the Company's ability to maintain or expand its intellectual property position, the timing and success of planned or existing clinical trials and anticipated levels of revenues and expenses and others, all as described Company's Registration Statement on Form F-10 and other filings with the U.S. Securities and Exchange Commission.*

###